search
Back to results

E-monitoring of PULMonary Function in Patients With Duchenne Muscular Dystrophy at Home" (E-PULMoDMD)

Primary Purpose

Duchenne Muscular Dystrophy (DMD)

Status
Recruiting
Phase
Not Applicable
Locations
Poland
Study Type
Interventional
Intervention
AioCare spirometer
telerehabiliation of the respiratory system
Sponsored by
Medical University of Gdansk
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Duchenne Muscular Dystrophy (DMD) focused on measuring AioCare spirometer, home spirometry, spirometry e-monitoring, pulmonary rehabilitation, digital medicine, e-health

Eligibility Criteria

7 Years - 17 Years (Child)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • male, ≥7 years and <18 years of age at the time of enrollment in the study;
  • ability to perform spirometry;
  • stated willingness to comply with all study procedures and availability for the duration of the study.

Exclusion Criteria:

  • no consent to participate in the study;
  • patients under 7 years of age or above 18 years of age;
  • inability to perform spirometry

Sites / Locations

  • Medical UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

No Intervention

Arm Label

arm with intervention (AioCare spirometry)

arm with intervention (AioCare spirometry with telerehabilitation)

arm with intervention (telerehabilitation)

control arm (no intervention)

Arm Description

50 participants with DMD aged 7-17 years, subjected to home electronic monitoring

50 participants with DMD aged 7-17 years, subjected to home electronic monitoring with the AioCare device and pulmonary rehabilitation exercises

50 participants with DMD aged 7-17 years, subjected to pulmonary rehabilitation exercises

50 participants with DMD aged 7-17 years, subject to a standard of care

Outcomes

Primary Outcome Measures

Change from Baseline of the mean Forced Vital Capacity in Liters measured by home and hospital spirometry in DMD participants with vs without respiratory telerehabilitation
Some studies showed that respiratory function declines at a rate of 6-11% annually in patients with DMD. A major component of respiratory dysfunction seems to be a decline of inspiratory muscle weakness. Methods of improving the functioning of the muscles of the respiratory system are constantly sought. One of the key factors that can improve the function of respiratory muscles is proper rehabilitation. The proposition is implementation of telerehabilitation of respiratory muscle together with e-monitoring pulmonary function at home.
Change from Baseline of the mean Forced Vital Capacity in %predicted value measured by home and hospital spirometry in DMD participants with vs without respiratory telerehabilitation
Some studies showed that respiratory function declines at a rate of 6-11% annually in patients with DMD. A major component of respiratory dysfunction seems to be a decline of inspiratory muscle weakness. Methods of improving the functioning of the muscles of the respiratory system are constantly sought. One of the key factors that can improve the function of respiratory muscles is proper rehabilitation. The proposition is implementation of telerehabilitation of respiratory muscle together with e-monitoring pulmonary function at home.

Secondary Outcome Measures

Possibility of home e-monitoring of pulmonary function in patients with Duchenne Muscular Dystrophy in the Covid-19 pandemic
number of the days with performed spirometry test per patient during the monitoring period number and percent of correct spirometry parameters.
The number of the participants who performed at least one correct spirometry examination
Feasibility of home e-monitoring of pulmonary function in patients with Duchenne Muscular Dystrophy in the Covid-19 pandemic measured by The number of the participants who performed at least one correct spirometry examination
the difference in the value of spirometry results (FVC %pv, L) between home spirometry and spirometry in the hospital
Feasibility of home e-monitoring of pulmonary function in patients with Duchenne Muscular Dystrophy in the Covid-19 pandemic measured by The number of the participants who performed at least one correc the difference in the value of spirometry results (FVC %pv, L) between home spirometry and spirometry in the hospital

Full Information

First Posted
September 22, 2021
Last Updated
August 23, 2022
Sponsor
Medical University of Gdansk
search

1. Study Identification

Unique Protocol Identification Number
NCT05516745
Brief Title
E-monitoring of PULMonary Function in Patients With Duchenne Muscular Dystrophy at Home"
Acronym
E-PULMoDMD
Official Title
E-monitoring of Pulmonary Function in Patients With Duchenne Muscular Dystrophy Undergoing Respiratory Rehabilitation at Home"
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Recruiting
Study Start Date
March 20, 2021 (Actual)
Primary Completion Date
February 2025 (Anticipated)
Study Completion Date
March 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medical University of Gdansk

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Duchenne muscular dystrophy (DMD) is the most common, progressive, irreversible muscular dystrophy. The pulmonary function is crucial for the duration of life in this disease. The European Respiratory Society is currently focused on digital health, seeking to define the realistic innovations for digital respiratory medicine to support professionals and patients during the COVID-19 pandemic. This study aimed to investigate whether it is possible to monitor pulmonary function at home by using an individual electronical spirometry system in children with Duchenne muscular dystrophy DMD. The second aim of the study is the implementation of respiratory telerehabilitation and the assessment of its impact on pulmonary function (FVC).
Detailed Description
Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy. DMD is a genetically determined, progressive, irreversible disease in which dystrophin dysfunction in skeletal and multiple organ muscles is fatal before the age of 20 years. Respiratory muscle failure is the most common cause of death. In the first years of life, the respiratory system of children with DMD is efficient and does not differ from that of healthy peers. From the age of 7 years, the parameters of lung function no longer increase, and between the ages of 10 to 12 years, when the child loses the ability to walk independently, the lung function rapidly deteriorates. Currently, it is not possible to cure the disease, but appropriate medical management may improve the quality of life and prolong the survival of patients with DMD. The basic tasks include the initiation of early monitoring of respiratory system functions. It is recommended that measurement of lung function is started from the age of 5 years. Taking the measurement at such an early age is aimed at familiarizing and teaching the child about this type of systematic examination and determining the individual maximum parameters of lung function in each child. Thanks to systematic measurements, it is possible to detect any sharp deterioration as well as the moment when the decreasing lung function requires respiratory support, so-called non-invasive ventilation (NIV). According to the standards, lung function is assessed by spirometry, which should be performed at least once a year, at least every 6 months after losing independent walking, and every 3 months after starting non-invasive ventilation. The spirometry test assesses forced vital capacity (FVC), which is considered a marker of disease progression. An FVC value below 2.1 L is a rationale to start supporting the cough reflex, and below 1 L is an indication to start respiratory support, i.e. NIV. Implementation of the above-mentioned tests often encounters difficulties that increase when the child loses independent walking. Additionally, during the COVID pandemic, spirometry was included in the procedures generating aerosols, i.e. high risk of SARS-CoV-2 virus transmission. Therefore, it has become necessary to look for other methods of measuring and monitoring lung function in children with DMD. The presented project aims to evaluate the measurement of lung function at home using an individual spirometer called an AIOCARE. The AioCare spirometer is a small, convenient device that can be used anywhere. The device enables systematic non-invasive monitoring of lung parameters (including FVC measurement) at home in children over 5 years of age. The child inhales and exhales forcefully through a mouthpiece with antibacterial and antiviral filters. The test results are sent from the AioCare spirometer via the AioCare application for iOS and Android (as used by all current smartphones). Communication between the AioCare spirometer and the application takes place via a Bluetooth 4.0 (BT LE) connection. The spirometry results are available to the practitioner in real-time in the AIOCARE Doctor panel. Additionally, a module with exercises for training respiratory muscles, included in an additional smartphone application, will be added to the daily spirometry test as part of the project. It will be a series of 4 exercises aimed at strengthening respiratory muscles, to be performed before the spirometry test. The assumption of the exercises is the possibility of performing them independently, at home, without the assistance of a physiotherapist, and without the use of additional equipment. Participants will perform forced exhalation exercises with a relaxed epiglottis, exercises to improve the mechanics of the chest and the mobility of the shoulder girdle. The exercises will be performed each day. The duration of the exercises is approximately 7 minutes. The exercise program will be recorded in the form of an instructional video. Pulmonary rehabilitation is one of the key issues in DMD patient management. The combination of systematic lung function measurement with home respiratory rehabilitation is an innovative project. It is a non-invasive test, and the measurement is intended to improve the quality of life of DMD patients. Aims of the study: to assess pulmonary function for 12 months using home electronic monitoring (AioCare System) in DMD participants aged 7-18 years (number of participants with increase FVC %pv, L value). to assess the acceptance of electronic home monitoring of a respiratory system in this group of patients (number of participants accepted home e-monitoring, survey). to compare the results from home electronic spirometry (AioCare) with results from hospital spirometry (Jaeger, Germany) - (value of FVC%pv, L). to investigate whether it is possible to conduct respiratory physical therapy with the use of telerehabilitation in DMD patients (number of patients accepted telerehabilitation, survey). to evaluate the impact of home telerehabilitation on pulmonary function (number of patients with increased FVC%pv, L value) to assess the quality of life of patients subjected to electronic monitoring and pulmonary rehabilitation vs. not subjected Study group: 200 participants with DMD aged 7-18 years, in the 4 arms (50 participants each): (1) subjected to home electronic monitoring exercises with the AIOCARE device, (2) home electronic monitoring with AioCareand pulmonary rehabilitation; (3) telerehabilitation of respiratory system; (4) control group - no interventions. Duration of the project March 2021 - March 2025.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Duchenne Muscular Dystrophy (DMD)
Keywords
AioCare spirometer, home spirometry, spirometry e-monitoring, pulmonary rehabilitation, digital medicine, e-health

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Model Description
4 arms - arm - AioCare device spirometry arm - AioCare device spirometry+ telerehabilitation of the respiratory system arm - telerehabilitation of the respiratory system arm - control arm - standard of care (no monitoring, no telerehabilitation)
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
arm with intervention (AioCare spirometry)
Arm Type
Experimental
Arm Description
50 participants with DMD aged 7-17 years, subjected to home electronic monitoring
Arm Title
arm with intervention (AioCare spirometry with telerehabilitation)
Arm Type
Experimental
Arm Description
50 participants with DMD aged 7-17 years, subjected to home electronic monitoring with the AioCare device and pulmonary rehabilitation exercises
Arm Title
arm with intervention (telerehabilitation)
Arm Type
Experimental
Arm Description
50 participants with DMD aged 7-17 years, subjected to pulmonary rehabilitation exercises
Arm Title
control arm (no intervention)
Arm Type
No Intervention
Arm Description
50 participants with DMD aged 7-17 years, subject to a standard of care
Intervention Type
Device
Intervention Name(s)
AioCare spirometer
Intervention Description
In the first part of the trial, all participants from arms 1 and 2 will receive the AioCare spirometer (Healtup, Poland) to home-based monitoring pulmonary function. Hospital spirometry examinations (Jaeger, Germany) evaluating disease progression will be performed periodically. There are to be follow-up visits after 3 months and after 6 months. The end-point visit is planned for 12 months.
Intervention Type
Other
Intervention Name(s)
telerehabiliation of the respiratory system
Intervention Description
A major component of respiratory dysfunction seems to be a decline of respiratory muscle weakness. The proposition is respiratory telerehabilitation to improve the function of respiratory muscles. Telerehabilitation includes breathing exercises for use at home. The participants will be trained in the hospital and will receive video presentations to support the exercises at home.
Primary Outcome Measure Information:
Title
Change from Baseline of the mean Forced Vital Capacity in Liters measured by home and hospital spirometry in DMD participants with vs without respiratory telerehabilitation
Description
Some studies showed that respiratory function declines at a rate of 6-11% annually in patients with DMD. A major component of respiratory dysfunction seems to be a decline of inspiratory muscle weakness. Methods of improving the functioning of the muscles of the respiratory system are constantly sought. One of the key factors that can improve the function of respiratory muscles is proper rehabilitation. The proposition is implementation of telerehabilitation of respiratory muscle together with e-monitoring pulmonary function at home.
Time Frame
12 months
Title
Change from Baseline of the mean Forced Vital Capacity in %predicted value measured by home and hospital spirometry in DMD participants with vs without respiratory telerehabilitation
Description
Some studies showed that respiratory function declines at a rate of 6-11% annually in patients with DMD. A major component of respiratory dysfunction seems to be a decline of inspiratory muscle weakness. Methods of improving the functioning of the muscles of the respiratory system are constantly sought. One of the key factors that can improve the function of respiratory muscles is proper rehabilitation. The proposition is implementation of telerehabilitation of respiratory muscle together with e-monitoring pulmonary function at home.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Possibility of home e-monitoring of pulmonary function in patients with Duchenne Muscular Dystrophy in the Covid-19 pandemic
Description
number of the days with performed spirometry test per patient during the monitoring period number and percent of correct spirometry parameters.
Time Frame
4 weeks
Title
The number of the participants who performed at least one correct spirometry examination
Description
Feasibility of home e-monitoring of pulmonary function in patients with Duchenne Muscular Dystrophy in the Covid-19 pandemic measured by The number of the participants who performed at least one correct spirometry examination
Time Frame
4 weeks
Title
the difference in the value of spirometry results (FVC %pv, L) between home spirometry and spirometry in the hospital
Description
Feasibility of home e-monitoring of pulmonary function in patients with Duchenne Muscular Dystrophy in the Covid-19 pandemic measured by The number of the participants who performed at least one correc the difference in the value of spirometry results (FVC %pv, L) between home spirometry and spirometry in the hospital
Time Frame
4 weeks

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
7 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: male, ≥7 years and <18 years of age at the time of enrollment in the study; ability to perform spirometry; stated willingness to comply with all study procedures and availability for the duration of the study. Exclusion Criteria: no consent to participate in the study; patients under 7 years of age or above 18 years of age; inability to perform spirometry
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Eliza Wasilewska, MD,PhD
Phone
+48 56 349 2625
Email
ewasilewska@gumed.edu.pl
First Name & Middle Initial & Last Name or Official Title & Degree
Eliza Wasilewska, MD,PhD
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eliza Wasilewska, MD,PhD
Organizational Affiliation
Medical University Gdansk
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical University
City
Gdańsk
ZIP/Postal Code
80-292
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eliza Wasilewska, MD,PhD
Phone
+48 56 349 2625
Email
ewasilewska@gumed.edu.pl

12. IPD Sharing Statement

Citations:
PubMed Identifier
29395989
Citation
Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, Case LE, Clemens PR, Hadjiyannakis S, Pandya S, Street N, Tomezsko J, Wagner KR, Ward LM, Weber DR; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018 Mar;17(3):251-267. doi: 10.1016/S1474-4422(18)30024-3. Epub 2018 Feb 3. Erratum In: Lancet Neurol. 2018 Apr 4;:
Results Reference
result
PubMed Identifier
29395990
Citation
Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, Case LE, Cripe L, Hadjiyannakis S, Olson AK, Sheehan DW, Bolen J, Weber DR, Ward LM; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018 Apr;17(4):347-361. doi: 10.1016/S1474-4422(18)30025-5. Epub 2018 Feb 3.
Results Reference
result
PubMed Identifier
15302625
Citation
Finder JD, Birnkrant D, Carl J, Farber HJ, Gozal D, Iannaccone ST, Kovesi T, Kravitz RM, Panitch H, Schramm C, Schroth M, Sharma G, Sievers L, Silvestri JM, Sterni L; American Thoracic Society. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am J Respir Crit Care Med. 2004 Aug 15;170(4):456-65. doi: 10.1164/rccm.200307-885ST. No abstract available.
Results Reference
result
PubMed Identifier
11751186
Citation
Phillips MF, Quinlivan RC, Edwards RH, Calverley PM. Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy. Am J Respir Crit Care Med. 2001 Dec 15;164(12):2191-4. doi: 10.1164/ajrccm.164.12.2103052.
Results Reference
result
PubMed Identifier
17711917
Citation
Toussaint M, Chatwin M, Soudon P. Mechanical ventilation in Duchenne patients with chronic respiratory insufficiency: clinical implications of 20 years published experience. Chron Respir Dis. 2007;4(3):167-77. doi: 10.1177/1479972307080697.
Results Reference
result
PubMed Identifier
28397169
Citation
LoMauro A, D'Angelo MG, Aliverti A. Sleep Disordered Breathing in Duchenne Muscular Dystrophy. Curr Neurol Neurosci Rep. 2017 May;17(5):44. doi: 10.1007/s11910-017-0750-1.
Results Reference
result
PubMed Identifier
16055882
Citation
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38. doi: 10.1183/09031936.05.00034805. No abstract available.
Results Reference
result
Links:
URL
https://healthcloud.aiocare.com
Description
AioCare description

Learn more about this trial

E-monitoring of PULMonary Function in Patients With Duchenne Muscular Dystrophy at Home"

We'll reach out to this number within 24 hrs